Lifeward (LFWD) Hisse Özeti
Bir tıbbi cihaz şirketi olan Lifeward Ltd. Amerika Birleşik Devletleri, Avrupa, Almanya, Asya-Pasifik ve uluslararası alanda fiziksel ve nörolojik rahatsızlıkları olan bireyler için rehabilitasyon ve günlük yaşamda hareketlilik ve zindelik sağlayan teknolojiler tasarlamakta, geliştirmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
LFWD Community Fair Values
Create NarrativeSee what 11 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Lifeward Ltd. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$7.22 |
| 52 Haftanın En Yüksek Seviyesi | US$10.56 |
| 52 Haftanın En Düşük Seviyesi | US$4.14 |
| Beta | 0.37 |
| 1 Aylık Değişim | -6.11% |
| 3 Aylık Değişim | -0.35% |
| 1 Yıllık Değişim | -13.60% |
| 3 Yıllık Değişim | -87.66% |
| 5 Yıllık Değişim | -93.95% |
| Halka arzdan bu yana değişim | -99.90% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 18
LFWD: Long Term Safety Data Will Support Stock Upside Potential
Analysts have modestly adjusted their price target on Lifeward, keeping fair value steady at $20.00. They fine tuned assumptions around the discount rate, profit margin, and future P/E to reflect updated valuation work, without a clear directional shift in the overall outlook.Anlatı Güncellemesi • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.Anlatı Güncellemesi • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.Recent updates
Anlatı Güncellemesi • Jun 18
LFWD: Long Term Safety Data Will Support Stock Upside Potential
Analysts have modestly adjusted their price target on Lifeward, keeping fair value steady at $20.00. They fine tuned assumptions around the discount rate, profit margin, and future P/E to reflect updated valuation work, without a clear directional shift in the overall outlook.Anlatı Güncellemesi • Jun 04
LFWD: Higher Expected Revenue And Future P/E Multiple Will Support Upside
Analysts have raised their price target for Lifeward to $10 from $4.50, citing updated assumptions on revenue growth, profit margins, discount rate, and future P/E that support a higher valuation framework. What's in the News On May 15, 2026, Lifeward said it will not be able to file its next 10-Q by the SEC deadline, indicating a delay in its upcoming quarterly report.Anlatı Güncellemesi • May 16
LFWD: Lower Discount Rate And Higher P/E Assumptions Support Upside Potential
Analysts have lifted their price target on Lifeward to $10 from $4.50, citing updated assumptions around discount rates, long term profit margins, and future P/E levels that feed into their fair value framework. Analyst Commentary Analysts revising their fair value frameworks for Lifeward point to changes in discount rates, long term margin assumptions, and targeted P/E levels as key drivers behind the new US$10 price target.
Anlatı Güncellemesi • Apr 30
LFWD: Higher Fair Value Assumptions Will Shape Future P E Repricing
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions related to fair value, discount rate, revenue growth, profit margin and future P/E estimates. Analyst Commentary Bearish analysts describe the move to a US$10 price target as a recalibration rather than a clear vote of confidence, pointing out that the new target still reflects uncertainty around how Lifeward can deliver on the assumptions used in updated fair value work.
Anlatı Güncellemesi • Apr 15
LFWD: Higher Risk Reward View Will Support Future Upside Potential
Analysts have raised their price target on Lifeward to $10 from $4.50, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple that together change their view of the company’s balance of risk and reward. Analyst Commentary Bullish analysts are framing the new US$10 price target as a reassessment of Lifeward’s potential risk and reward, rather than just a reaction to short term news.Anlatı Güncellemesi • Mar 31
LFWD: Higher Fair Value Assumptions Will Support Future Cash Flow
Analysts have lifted the price target for Lifeward to $10 from $4.50, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Analysts lifting the Lifeward price target to $10 from $4.50 are updating their view of what they see as fair value, based on refreshed assumptions for revenue growth, profitability, discount rates, and future P/E levels.Anlatı Güncellemesi • Mar 17
LFWD: Reverse Split And Convertible Notes Will Support Future Upside
Analysts have raised their price target on Lifeward from $10.00 to about $120.00, citing updated views on revenue growth, profit margins, and a lower assumed future P/E multiple. What's in the News Lifeward plans dedicated clinic days with Shirley Ryan AbilityLab in Chicago starting in the second quarter of 2026, focused on evaluation and access to the FDA cleared ReWalk Personal Exoskeleton for people with spinal cord injury (Key Developments).Anlatı Güncellemesi • Mar 03
LFWD: Reverse Split And New Financing Will Support Future Cash Flow
Analysts have lifted their price target for Lifeward to $87.00, supported by updated assumptions around fair value, discount rate, revenue growth, profit margin, and a lower future P/E multiple. What's in the News Lifeward plans a 1 for 12 reverse split of its ordinary shares, effective at the open of trading on February 24, 2026.Anlatı Güncellemesi • Feb 17
LFWD: Convertible Notes And Share Actions Will Drive Future P E Repricing
Analysts have modestly adjusted their price target on Lifeward, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that slightly refine their view of the company’s risk and earnings power in dollar terms. What's in the News Lifeward plans a Special and Extraordinary Shareholders Meeting on March 12, 2026 at its Hudson, Massachusetts offices to address corporate matters previously approved in principle at earlier meetings (company event filing).Anlatı Güncellemesi • Feb 03
LFWD: New Convertible Funding And Reverse Split Will Support Future Upside
Narrative Update on Lifeward Analysts have slightly reduced their price target for Lifeward, citing small adjustments to the discount rate and future P/E assumptions, along with modest changes to expected revenue growth and profit margins. What's in the News Lifeward completed a private placement on November 14, 2025, issuing secured convertible promissory notes with an aggregate principal of $3,000,000, carrying 15% annual interest and convertible into ordinary shares at $0.45 per share, with participation from Oramed Ltd and maturity on May 14, 2026 (Key Developments).Anlatı Güncellemesi • Jan 20
LFWD: Future P/E Repricing Will Rely On Successful Convertible Note Execution
Analysts have raised their price target for Lifeward to reflect higher modelled revenue growth of about 53% and a very large future P/E multiple, even as they factor in a lower profit margin and a slightly higher discount rate. What's in the News Lifeward entered into a private placement agreement to issue Senior Secured Convertible Notes with a principal amount of $20,000,000 and accompanying warrants, with the notes initially convertible at $0.45 per share and accruing 8.0% annual interest that may rise to 15.0% in the event of default (Key Developments).Anlatı Güncellemesi • Jan 06
LFWD: Reverse Split And New Funding Will Set Up Future Upside
Analysts have reduced their fair value estimate for Lifeward from US$13.00 to US$10.00. They attribute this change to more conservative assumptions on revenue growth, profit margins and the P/E multiple they apply to the company.Anlatı Güncellemesi • Dec 17
LFWD: Improved Capital Structure Will Support Future Cash Flow Potential
Analysts have nudged their price target for Lifeward slightly higher to reflect marginally lower perceived risk and modest improvements in long term profitability and valuation assumptions, even as their underlying fair value estimate remains anchored around $5.17 per share. What's in the News Lifeward completed a $3 million private placement via secured convertible promissory notes bearing 15% interest, convertible at $0.45 per share and maturing May 14, 2026, with participation from Oramed Ltd.Anlatı Güncellemesi • Dec 03
LFWD: Improved Medicare Reimbursement Trends Will Support Future Cash Flow
Narrative Update on Lifeward The analyst price target for Lifeward has been revised upward to approximately 5.17 dollars per share from 5.17 dollars previously. This reflects analysts' expectations for faster revenue growth, improved profit margins, and a lower future price to earnings multiple.Anlatı Güncellemesi • Nov 19
LFWD: Rising Medicare Approvals And New Funding Will Support Revenue Outlook
Analysts have significantly lowered their price target for Lifeward from $8.00 to approximately $5.17. They cite more conservative revenue growth projections and a notable reduction in expected profit margins.Analiz Makalesi • Sep 25
Even With A 27% Surge, Cautious Investors Are Not Rewarding Lifeward Ltd.'s (NASDAQ:LFWD) Performance Completely
Despite an already strong run, Lifeward Ltd. ( NASDAQ:LFWD ) shares have been powering on, with a gain of 27% in the...Anlatı Güncellemesi • Aug 16
FDA Clearance And Expanded Payer Channels Will Drive Advanced Mobility
The consensus price target for Lifeward has been revised down to $8.00, primarily reflecting a sharp decrease in its future P/E multiple, while profitability remains stable. What's in the News Lifeward reset full-year 2025 earnings guidance under new management, targeting revenue of $24–$26 million.Analiz Makalesi • Jun 19
Many Still Looking Away From Lifeward Ltd. (NASDAQ:LFWD)
With a price-to-sales (or "P/S") ratio of 0.5x Lifeward Ltd. ( NASDAQ:LFWD ) may be sending very bullish signals at the...Yeni Anlatı • May 11
AlterG NEO And ReWalk 70 Will Shape Future Market Opportunities
Established lump sum payments and expanded into U.S. workers' compensation, creating stable revenue streams and improving net margins through efficient claim processing.Analiz Makalesi • Feb 05
Market Cool On Lifeward Ltd.'s (NASDAQ:LFWD) Revenues Pushing Shares 50% Lower
Lifeward Ltd. ( NASDAQ:LFWD ) shareholders won't be pleased to see that the share price has had a very rough month...Analiz Makalesi • Oct 30
Not Many Are Piling Into Lifeward Ltd. (NASDAQ:LFWD) Stock Yet As It Plummets 25%
Unfortunately for some shareholders, the Lifeward Ltd. ( NASDAQ:LFWD ) share price has dived 25% in the last thirty...Analiz Makalesi • Oct 15
Here's Why Lifeward (NASDAQ:LFWD) Must Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analiz Makalesi • Aug 01
ReWalk Robotics Ltd. (NASDAQ:LFWD) Soars 26% But It's A Story Of Risk Vs Reward
ReWalk Robotics Ltd. ( NASDAQ:LFWD ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Analiz Makalesi • May 30
Is ReWalk Robotics (NASDAQ:LFWD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Hissedar Getirileri
| LFWD | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | 2.4% | 1.9% | 0.9% |
| 1Y | -13.6% | -16.1% | 17.5% |
Getiri vs. Endüstri: LFWD geçen yıl boyunca % -16.1 oranında getiri sağlayan US Medical Equipment sektörüyle eşleşti.
Getiri vs Piyasa: LFWD geçen yıl % 17.5 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| LFWD volatility | |
|---|---|
| LFWD Average Weekly Movement | 7.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: LFWD son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: LFWD 'nin haftalık oynaklığı ( 8% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2001 | 81 | William Grant | golifeward.com |
Bir tıbbi cihaz şirketi olan Lifeward Ltd., Amerika Birleşik Devletleri, Avrupa, Almanya, Asya-Pasifik ve uluslararası alanda fiziksel ve nörolojik rahatsızlıkları olan bireyler için rehabilitasyon ve günlük yaşamda hareketlilik ve zindelik sağlayan teknolojiler tasarlamakta, geliştirmekte ve ticarileştirmektedir. Omurilik yaralanması olan bireyler için ReWalk kişisel dış iskelet ve rehabilitasyon dış iskelet cihazları; inme nedeniyle alt ekstremite engeli olan bireylerin rehabilitasyonunda kullanılmak üzere tasarlanmış yumuşak bir dış giysi olan ReStore Exo-Suit; fiziksel ve nörolojik rehabilitasyon ve atletik eğitimde kullanılmak üzere AlterG Anti-Yerçekimi Sistemi; MyoCycle cihazları ve inme sonrası bireylerin ev ve toplum kullanımı için kişisel yumuşak bir dış giysi olan ReBoot'u sunmaktadır. Şirket, ürünlerini doğrudan kurumlara ve bireylere ve ayrıca üçüncü taraf distribütörler aracılığıyla pazarlamakta ve satmaktadır.
Lifeward Ltd. Temel Bilgiler Özeti
| LFWD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$19.70m |
| Kazançlar(TTM) | -US$25.87m |
| Gelir(TTM) | US$20.92m |
1.0x
P/S Oranı-0.8x
F/K OranıLFWD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| LFWD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$20.92m |
| Gelir Maliyeti | US$13.28m |
| Brüt Kâr | US$7.65m |
| Diğer Giderler | US$33.52m |
| Kazançlar | -US$25.87m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -9.19 |
| Brüt Marj | 36.55% |
| Net Kâr Marjı | -123.66% |
| Borç/Özkaynak Oranı | 115.7% |
LFWD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/31 06:10 |
| Gün Sonu Hisse Fiyatı | 2026/07/31 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Lifeward Ltd. 7 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Matthew Taylor | Barclays |
| William Plovanic | Canaccord Genuity |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |